Essayer OR - Gratuit
India, critical player in global laboratory equipment scene
Chronicle Pharmabiz
|October 16, 2025
THE vibrant Indian laboratory equipment and analytical instruments market is poised for significant growth, fuelled by rising investments in research and development (R&D), contract research projects and increasing demand for advanced laboratory techniques.
The sector is further propelled by innovation and strategic collaborations. The rising startup activity and increased foreign direct investment in lab equipment and analytical instrumentation, position India as a critical player in the space.
According to a market report, laboratory equipment services market size is estimated to reach $22.1 billion by 2027, growing at a CAGR of 11.1 per cent during the forecast period 2022-2027 with the Asia-Pacific region expected to be the highest contributor to this growth.
The big names in the lab market in India investing in R&D include Agilent Technologies; Thermo Fisher Scientific Inc.; Waters Corporation; Danaher Corporation; Merck Eppendorf AG; PerkinElmer Inc; Pace Analytical Services Inc.
The age of automation
In an age of Industry 4.0 automation, robotics, Internet of Things (IoT), Artificial Intelligence (AI), Machine Learning (ML) and advanced imaging techniques are signalling a shift in investment priorities. Advances in imaging technologies, like high-resolution microscopy and imaging software allow for detailed and accurate analysis in research and diagnostics. 3D Printing technology helps develop custom lab equipment and prototypes, allowing for rapid development and testing of new devices.
No doubt technology infusion is streamlining laboratory processes, increasing efficiency, and decreasing human error in sample analysis and data collection. AI and ML are enabling advanced data analysis, predictive maintenance, and personalized medicine, allowing for more accurate and faster results. Further, IoT-enabled devices are improving connectivity between lab instruments, facilitating real-time monitoring and data sharing, which speeds up decision-making.
Cette histoire est tirée de l'édition October 16, 2025 de Chronicle Pharmabiz.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Chronicle Pharmabiz
Chronicle Pharmabiz
US FDA fortifies alliance with Telangana DCA
A high-level delegation from the US FDA concluded a significant meeting with the DCA in Telangana, two days ago, at the DCA office in Hyderabad.
2 mins
December 11, 2025
Chronicle Pharmabiz
India exploring possibilities to expand WHO standards for Indian medicines
INDIA is looking at possibilities to expand the World Health Organisation (WHO) global benchmarking standards for medicines, in order to unify and strengthen the drug regulatory mechanism for safety, quality and efficacy of medicines sold in the country.
1 min
December 11, 2025
Chronicle Pharmabiz
Eli Lilly gets US FDA approval for Jaypirca
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor.
1 mins
December 11, 2025
Chronicle Pharmabiz
Haryana DCA focuses on quality overhaul
THE Haryana drug control administration (DCA) is undertaking a major organizational overhaul focused on quality system upgrades and regulatory capacity building, particularly in response to the revised Schedule M norms.
2 mins
December 11, 2025
Chronicle Pharmabiz
DoC seeks inputs on trade issues faced with Japan
THE Department of Commerce (DoC), under the Union Commerce Ministry, has sought inputs from the industry on specific issues being faced in pharma trade with Japan.
1 min
December 11, 2025
Chronicle Pharmabiz
AIOCD asks traders to strictly comply with ban on 35 FDCs
THE All India Organisation of Chemists and Druggists (AIOCD) has issued an urgent internal circular to all its state and Union territory trade bodies, demanding immediate and strict compliance with the ban on 35 fixed dose combinations (FDCs).
3 mins
December 11, 2025
Chronicle Pharmabiz
US FDA approves Bristol Myers Squibb's Breyanzi
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.
2 mins
December 11, 2025
Chronicle Pharmabiz
CN Water presents AQU@Sense MB
CN Water is now combining core water-system expertise with digital assurance has launched AQU@Sense which delivers microbial test results in under 30 minutes, replacing traditional 5 to 7 days culture based methods.
1 min
December 11, 2025
Chronicle Pharmabiz
Pharma logistics sees policy push as key catalyst for growth
INDIAN pharma's logistics sector is getting major boost from emerging policy support.
2 mins
December 11, 2025
Chronicle Pharmabiz
Lack of financial aid, expertise mar MSME prospects to meet revised Sch M deadline
INDUSTRY experts have raised alarm that lack of financial assistance and guidance on technical expertise have marred pharma MSMEs’ prospects to comply with revised Schedule M guidelines of December 31, 2025.
2 mins
December 11, 2025
Listen
Translate
Change font size
